PCM
CPRX

Penserra Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Penserra Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,292
Closed -$53K – 1114
2025
Q4 		$53K Buy
+2,292
New +$51.1K ﹤0.01% 761
2025
Q2 		– Sell
-90,552
Closed -$2.19M – 1049
2025
Q1 		$2.19M Buy
+90,552
New +$2.04M 0.04% 291
2023
Q2 		– Sell
-164,071
Closed -$2.72M – 1271
2023
Q1 		$2.72M Buy
164,071
+14,230
+9% +$235K 0.06% 272
2022
Q4 		$2.79M Buy
+149,841
New +$2.31M 0.06% 308

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Penserra Capital Management's CPRX Position: Q1 2026 in Review

Penserra Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 2,292 shares — an estimated $53K sold.

Penserra Capital Management first reported a position in CPRX in Q4 2022 and held it in 4 quarters. The position peaked at $2.79M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Penserra Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 2,292 Catalyst Pharmaceutical shares in Q1 2026, an estimated $53K.
  • Penserra Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 4 quarters.
  • Penserra Capital Management's Catalyst Pharmaceutical position peaked at $2.79M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.